Key Highlights
•
Reeler mice, a model for neurodevelopmental disorders, show significant deficits in recognizing novel textures, revealing key links to learning and memory impairment. This finding underscores the importance of the reeler gene in sensory processing and could pave the way for new therapeutic targets for related neurological conditions.
Source →
•
A new study on Alzheimer’s disease research reveals that mentioning financial compensation during recruitment may paradoxically reduce enrollment rates, potentially due to conflicts with altruistic motives. This insight is critical for designing more effective recruitment strategies for longitudinal studies on neurodegenerative diseases.
Source →
•
A report from the Structure and Dimensions Subcommittee outlines the future of the Diagnostic and Statistical Manual of Mental Disorders (DSM), signaling a major shift toward a more dimensional approach. This evolution will profoundly impact the diagnosis and classification of neuropsychiatric conditions, including those related to neurodegeneration.
Source →
•
New appropriate use recommendations for the Alzheimer’s drug lecanemab highlight the ongoing challenge of securing reimbursement in the UK, despite its regulatory approval. This dilemma underscores the complex path from drug approval to patient access for new neurodegenerative disease therapies.
Source →
•
A teaching neuroimage report documents a rare case of bilateral Sturge-Weber syndrome occurring alongside Dyke-Davidoff-Masson syndrome changes. This case provides unique insights into the overlapping pathophysiology of these neurological conditions and their impact on brain structure.
Source →
Stay curious. Stay informed —
Science Briefing
